PTX3 as a diagnostic and prognostic biomarker in lung adenocarcinoma: a comprehensive analysis
PTX3 emerges as a dual biomarker for LUAD diagnosis and prognosis, with mechanistic ties to TME remodeling and therapeutic resistance, highlighting its potential for clinical translation.
Authors
- Na Li (ORCID: https://orcid.org/0000-0003-1869-201X)
- Shaobo Zhou (ORCID: https://orcid.org/0000-0001-5214-2973)
- Dina Haishaer
- Hongmei Zhao (ORCID: https://orcid.org/0000-0002-4520-0490)
Institutions
- Fujian Medical University (CN)
- Liaoning Provincial People's Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-06-19
- DOI
- https://doi.org/10.1007/s12672-025-02983-5
- Citations
- 2
- Primary Topic
- Biomarkers in Disease Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Wu Jieping Medical Foundation